Drug Rediscovery Group (DRG) is a pioneering brand that focuses on identifying, developing, and commercializing novel treatment opportunities in established drugs. By leveraging real-world clinical discoveries and medical research, DRG is able to expand upon proven medications and deliver high-value, safety-assured Phase-III-ready drug candidates. Their mission is to maximize the treatment value of existing drugs and eliminate missed treatment opportunities.

DRG utilizes a unique methodology that involves attracting impactful clinical discoveries and preparing them for commercialization. This approach increases the treatment potential of drugs, making them relevant for multiple patient populations. They aim to uncover the many treatment opportunities that often go unnoticed or unpromoted, expanding the range of uses for FDA-approved drugs.

With a track record of success, DRG's process starts with effective drugs, reducing the risk of failure. Their directed and optimized selection process further minimizes risk, time, and development costs. DRG offers next-generation solutions for conditions such as Erectile Dysfunction (ED), Pulmonary Arterial Hypertension, and ocular surface disorders.

They also prioritize combating the opioid epidemic by repurposing safe drugs to mitigate cravings and toxicity. With a diverse pipeline encompassing over 15 medical conditions, DRG is committed to revolutionizing various therapeutic areas including pain management, rheumatic diseases, ophthalmology, and infectious diseases. They actively seek collaboration and third-party partnership opportunities, making them a driving force in drug rediscovery